To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer

NCT05198531 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent / Metastatic Nasopharyngeal Cancer

Interventions

DRUG: TQB2858 Injection
DRUG: Anlotinib Hydrochloride Capsule
DRUG: Gemcitabine hydrochloride injection
DRUG: Cisplatin Injection

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.